Thalys Medical Technology Group Inc banner

Thalys Medical Technology Group Inc
SSE:603716

Watchlist Manager
Thalys Medical Technology Group Inc Logo
Thalys Medical Technology Group Inc
SSE:603716
Watchlist
Price: 22.72 CNY -3.36% Market Closed
Market Cap: ¥4.8B

Multiples-Based Value

The Multiples-Based Value for Thalys Medical Technology Group Inc (603716) under the Base Case is hidden CNY. Compared with the current market price of 22.72 CNY, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Thalys Medical Technology Group Inc Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Thalys Medical Technology Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Thalys Medical Technology Group Inc
SSE:603716
4.8B CNY 3.8 -19.9 -44.7 -44.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
367.6B USD 6 87.8 14.6 20.2
US
Amgen Inc
NASDAQ:AMGN
189.2B USD 5.1 24.5 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
176.3B USD 5.9 20.3 12.7 15.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.5B USD 9.2 28 21 22
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.2B USD 5.5 17.6 13 14.8
NL
argenx SE
XBRU:ARGX
42.2B EUR 11.9 38.2 41.3 42.1
AU
CSL Ltd
ASX:CSL
67.6B AUD 3 32.9 11.1 13.9
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
CN
Thalys Medical Technology Group Inc
SSE:603716
Average P/S: 3 063 003.1
3.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.2
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.6
NL
argenx SE
XBRU:ARGX
11.9
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.7
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
CN
Thalys Medical Technology Group Inc
SSE:603716
Average P/E: 35.6
Negative Multiple: -19.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.8
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.5
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.3
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
13%
1.4
NL
argenx SE
XBRU:ARGX
38.2
32%
1.2
AU
CSL Ltd
ASX:CSL
32.9
10%
3.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Thalys Medical Technology Group Inc
SSE:603716
Average EV/EBITDA: 18.3
Negative Multiple: -44.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
18%
0.7
NL
argenx SE
XBRU:ARGX
41.3
50%
0.8
AU
CSL Ltd
ASX:CSL
11.1
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Thalys Medical Technology Group Inc
SSE:603716
Average EV/EBIT: 20.4
Negative Multiple: -44.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.2
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.6
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.8
23%
0.6
NL
argenx SE
XBRU:ARGX
42.1
51%
0.8
AU
CSL Ltd
ASX:CSL
13.9
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett